8-K: Venus Concept Q2 2025: Revenue Dips Amid Strategic Shifts

Venus Concept Inc. reported a 5% year-over-year revenue decline to $15.7 million in Q2 2025, alongside strategic debt reduction and a planned $20 million asset sale.

Summary

• Total revenue for the second quarter of 2025 was $15.7 million, a 5% decrease year-over-year but a 15% increase quarter-over-quarter.
• U.S. revenue grew by $0.4 million, or 5%, year-over-year, driven by a 23% increase in cash systems sales.
• International revenue decreased by $1.3 million, or 18%, year-over-year.
• GAAP net loss for Q2 2025 was $11.7 million, an improvement compared to a $19.9 million net loss in Q2 2024.
• Adjusted EBITDA loss for Q2 2025 worsened to $8.8 million, compared to a $4.1 million loss in Q2 2024.
• Gross profit decreased by 20% to $9.4 million, with gross margin falling to 60.1% from 71.5% in the prior year.
• Operating expenses increased by 6% year-over-year to $18.5 million.
• The company announced a definitive agreement to sell its Venus Hair business for $20 million in an all-cash transaction.
• Multiple registered direct offerings in April and June 2025 raised approximately $3.9 million in gross proceeds.
• A debt-to-equity exchange on June 30, 2025, converted $6.5 million of subordinated convertible notes into Series Y preferred stock, contributing to $17.5 million in total converted debt this year.
• Cash and cash equivalents stood at $4.9 million as of June 30, 2025, with total debt obligations reduced to $34.3 million from $39.7 million at December 31, 2024.

Sentiment

Score: 4

Explanation: The company's core operational performance (revenue, gross profit, Adjusted EBITDA) is deteriorating year-over-year, indicating ongoing financial challenges. While strategic actions like debt reduction and an asset sale are positive steps towards long-term stability, the immediate financial results are weak, and the lack of guidance adds uncertainty.

Positives

• U.S. revenue increased by 5% year-over-year, driven by a 23% growth in cash systems sales.
• Total revenue showed solid sequential growth of 15% quarter-over-quarter.
• GAAP net loss significantly improved to $11.7 million from $19.9 million in the prior year period.
• Successfully executed multiple equity capital transactions, raising $3.9 million in gross proceeds.
• Completed debt-to-equity exchange transactions totaling $17.5 million, enhancing the balance sheet and capital structure.
• Entered into a definitive agreement to sell the Venus Hair business for $20 million, expected to strengthen the company by focusing on global medical aesthetics, improving revenue growth, lowering operating expenses, and enhancing cash flow.
• Total debt obligations decreased to $34.3 million as of June 30, 2025, from $39.7 million at December 31, 2024.

Negatives

• Total revenue decreased by 5% year-over-year to $15.7 million.
• International revenue declined by 18% year-over-year.
• Gross profit decreased by 20% to $9.4 million, and gross margin fell to 60.1% from 71.5% in the prior year.
• Adjusted EBITDA loss worsened to $8.8 million from $4.1 million in the prior year period.
• Operating loss increased to $9.0 million from $5.6 million in the prior year period.
• Operating expenses increased by 6% year-over-year to $18.5 million.
• The company is not providing financial guidance at this time due to ongoing strategic evaluations and market uncertainties.

Risks

• Customer uncertainty about economic stability negatively impacted capital equipment sales.
• Tighter third-party lending practices continue to affect capital equipment sales.
• Decrease in international revenue driven by the exit from unprofitable direct markets.
• Supply disruptions caused by the Israel-Iran conflict impacting production at the contract manufacturer's facility in Israel.
• The company is not providing financial guidance due to active dialogue with lenders and investors, ongoing evaluation of strategic alternatives, and assessment of potential trade disruptions.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that are in some cases beyond the company's control.

Future Outlook

The company is not providing financial guidance for fiscal year 2025 at this time due to active dialogue with lenders and investors, ongoing evaluation of strategic alternatives to maximize shareholder value, and assessment of potential trade disruptions. Management expects the sale of the Venus Hair business to strengthen the company by allowing a focus on the global medical aesthetics business, which is anticipated to improve revenue growth, lower operating expenses, enhance cash flow, and accelerate the path to long-term, sustainable profitability.

Management Comments

• "Our second quarter revenue results reflect strong execution in a continued challenging environment."
• "We delivered solid sequential growth in the second quarter, driven by 20% growth in total systems and subscription sales quarter-over-quarter."
• "We were particularly encouraged by year-over-year growth in the US business which led to a significant moderation of the decline year-over-year for the entire business."
• "Our focus remains on managing our cash burn through disciplined cost management and making targeted investments to support our long-term growth."
• "We have made considerable progress this year towards our strategic initiative to position the Company for long-term success."
• "We believe this transaction [Venus Hair sale] will strengthen the Company by allowing us to focus on our global medical aesthetics business which we expect will improve revenue growth, lower operating expenses, enhance the cash flow profile of the business and accelerate the path to long-term, sustainable profitability."

Industry Context

The company operates in a challenging environment, facing customer uncertainty about economic stability and tighter third-party lending practices, which have negatively impacted capital equipment sales in the medical aesthetic technology sector. The strategic decision to exit unprofitable direct international markets and focus on the core global medical aesthetics business reflects a broader industry trend of companies streamlining operations and optimizing portfolios in response to market pressures.

Legal Proceedings

• The Canada Revenue Agency (CRA) initiated an audit of the Canada Emergency Wage Subsidy Claim (CEWS) filed between 2020-2021, assessing a denial of 2020 claims and requesting repayment of $418,000. The company disputes this assessment and intends to challenge it.

Related Party Transactions

• On June 30, 2025, the company exchanged $6.5 million of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP for 325,651 shares of its Series Y preferred stock.

Stakeholder Impact

• Shareholders: Experienced dilution from multiple registered direct offerings and a reverse stock split. May benefit from the strategic asset sale and debt reduction if these actions lead to improved long-term profitability and shareholder value.
• Creditors: Benefit from the reduction in total debt obligations and debt-to-equity exchanges, improving the company's capital structure.
• Employees: Impacted by restructuring activities designed to improve operations and cost structure, as indicated by 'other adjustments' in the Adjusted EBITDA reconciliation.

Next Steps

• Management will host a conference call on August 14, 2025, at 5:00 p.m. Eastern Time to discuss the results.
• The company will continue its ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value.
• The company will continue to assess potential trade disruptions.

Key Dates

Recommendation

Despite some positive strategic actions like debt reduction and an asset sale, the company's core operational performance for Q2 2025 shows significant deterioration, including a 5% year-over-year revenue decline, a 20% drop in gross profit, and a worsening Adjusted EBITDA loss. The GAAP net loss improvement is largely due to lower debt extinguishment costs, not improved operations. The lack of financial guidance and ongoing market uncertainties further compound the risk. For a seasoned investor, the current financial trajectory and operational challenges suggest a 'Sell' to mitigate further losses, as the turnaround remains highly speculative with no clear immediate path to profitability.

Keywords

Venus Concept, VERO, medical aesthetics, financial results, Q2 2025, earnings, debt restructuring, capital raise, asset sale, revenue, net loss, EBITDA, corporate strategy